{"protocolSection": {"identificationModule": {"nctId": "NCT03030222", "orgStudyIdInfo": {"id": "1245.129"}, "organization": {"fullName": "Saint Luke's Health System", "class": "OTHER"}, "briefTitle": "Empagliflozin Impact on Hemodynamics in Patients With Heart Failure", "officialTitle": "Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure", "acronym": "EMBRACE-HF"}, "statusModule": {"statusVerifiedDate": "2021-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-07-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-03-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-03-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-01-20", "studyFirstSubmitQcDate": "2017-01-20", "studyFirstPostDateStruct": {"date": "2017-01-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-09-23", "resultsFirstSubmitQcDate": "2021-11-10", "resultsFirstPostDateStruct": {"date": "2021-12-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-11-10", "lastUpdatePostDateStruct": {"date": "2021-12-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Saint Luke's Health System", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device (a wireless hemodynamic monitoring system) implanted for non-study related clinical reasons.", "detailedDescription": "A 12-week randomized, double-blind, placebo-controlled trial to explore the effects of once-daily empagliflozin 10 mg on hemodynamic parameters (pulmonary artery pressures) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device implanted for non-study related clinical reasons."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["heart failure", "empagliflozin", "Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 65, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Empagliflozin", "type": "ACTIVE_COMPARATOR", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks", "interventionNames": ["Drug: Empagliflozin 10 mg Tab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks", "interventionNames": ["Drug: Placebo Oral Tablet"]}], "interventions": [{"type": "DRUG", "name": "Empagliflozin 10 mg Tab", "description": "Empagliflozin 10 mg Tab", "armGroupLabels": ["Empagliflozin"], "otherNames": ["Jardiance"]}, {"type": "DRUG", "name": "Placebo Oral Tablet", "description": "Empagliflozin matching placebo", "armGroupLabels": ["Placebo"], "otherNames": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Pulmonary Artery Diastolic Pressure From Baseline to End of Treatment Period (Defined as Average of Pulmonary Artery Diastolic Pressure Measurements Between Weeks 8-12) Between Empagliflozin and Placebo", "description": "Change in pulmonary artery diastolic pressure from baseline to end of treatment period (defined as average of pulmonary artery diastolic pressure measurements between weeks 8-12) between empagliflozin and placebo", "timeFrame": "Baseline to average between Weeks 8-12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Pulmonary Artery Diastolic Pressure at Each Interim Timepoint (Wks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12) Between Empagliflozin and Placebo.", "description": "Change from baseline in pulmonary artery diastolic pressure at each interim timepoint (wks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12) between empagliflozin and placebo.", "timeFrame": "Baseline to Weeks 1-12"}, {"measure": "Change in Pulmonary Artery Systolic Pressure From Baseline to End of Treatment Period (Week 12) Between Empagliflozin and Placebo.", "description": "Change in pulmonary artery systolic pressure from baseline to end of treatment period (week 12) between empagliflozin and placebo.", "timeFrame": "Baseline to Week 12"}, {"measure": "Change From Baseline in Pulmonary Artery Systolic Pressure at Each Interim Time Point (Wks 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12) Between Empagliflozin and Placebo.", "description": "Change from baseline in pulmonary artery systolic pressure at each interim time point (wks 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12) between empagliflozin and placebo.", "timeFrame": "Baseline to Weeks 1-12"}, {"measure": "Change in Mean Pulmonary Artery Pressure From Baseline to End of Treatment Period (Week 12) Between Empagliflozin and Placebo.", "description": "Change in mean pulmonary artery pressure from baseline to end of treatment period (week 12) between empagliflozin and placebo.", "timeFrame": "Baseline to Week 12"}, {"measure": "Change From Baseline in Mean Pulmonary Artery Pressure at Each Interim Time Point (Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) Between Empagliflozin and Placebo.", "description": "Change from baseline in mean pulmonary artery pressure at each interim time point (weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) between empagliflozin and placebo.", "timeFrame": "Baseline to Weeks 1-12"}, {"measure": "Change in Heart Failure Related Quality of Life, Using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) From Baseline to Follow-up (Defines as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the Kansas City Cardiomyopathy Questionnaire Overall Summary Score KCCQ-OS, a small but clinically meaningful change is considered to be \u2265 5 points.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Proportion of Patients With a \u2265 5 Point Increase From Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the Kansas City Cardiomyopathy Questionnaire Overall Summary Score KCCQ-OS, a small but clinically meaningful change is considered to be \u2265 5 points.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Change in 6 Minute Walk Test From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "Change in 6 minute walk test from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "Change in N-terminal pro b-type natriuretic peptide (NT-proBNP) from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Change in Brain Natriuretic Peptide (BNP) From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "Change in brain natriuretic peptide (BNP) from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Proportion of Patients With a \u2265 20% Decrease From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.", "description": "Proportion of patients with a \u2265 20% decrease from baseline in N-terminal pro b-type natriuretic peptide (NT-proBNP) at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Proportion of Patients With a \u2265 20% Decrease From Baseline in Brain Natriuretic Peptide (BNP) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.", "description": "Proportion of patients with a \u2265 20% decrease from baseline in brain natriuretic peptide (BNP) at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Proportion of Patients With Both a \u2265 5 Point Increase From Baseline in KCCQ-OS and a \u2265 20% Decrease From Baseline in NT-proBNP at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.", "description": "Proportion of patients with both a \u2265 5 point increase from baseline in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) and a \u2265 20% decrease from baseline in N-terminal pro b-type natriuretic peptide (NT-proBNP) at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the Kansas City Cardiomyopathy Questionnaire Overall Summary Score KCCQ-OS, a small but clinically meaningful change is considered to be \u2265 5 points.", "timeFrame": "Baseline to Week 6 and Week 12"}, {"measure": "Number of Participants With Diuretic Medication Adjustments During the Treatment Period Between Empagliflozin and Placebo", "description": "Number of Participants with Diuretic Medication Adjustments During the Treatment Period Between Empagliflozin and Placebo", "timeFrame": "Baseline to Week 12"}, {"measure": "Change in Hemoglobin A1c From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "Change in Hemoglobin A1c from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo.", "timeFrame": "Baseline to Week 6 and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Established diagnosis of heart failure (for at least 16 weeks prior to the screening visit) with either preserved (LVEF\\>40%) or reduced systolic function (LVEF\u226440%), due to either ischemic or non-ischemic etiology, documented by an imaging modality (echocardiography, nuclear imaging, LV angiography, magnetic resonance imaging) within the past 24 months.\n2. No major change in diuretic management for 48 hours prior to screening visit or 48 hours prior to randomization visit (major change defined by doubling of diuretic dose or addition of another diuretic medication)\n3. New York Heart Association (NYHA) class II, III or IV heart failure symptoms at the screening and randomization visit\n4. Presence of previously (\u2265 2 weeks prior to screening visit) implanted CardioMEMs pulmonary artery pressure monitor for a clinical indication unrelated to the study.\n5. Pulmonary artery diastolic pressure \u2265 12 mmHg at the time of the screening visit (last measurement available prior to the screening visit).\n6. Ability to provide informed consent prior to initiating screening visit procedures\n\nExclusion Criteria:\n\n1. Decompensated heart failure (hospitalization for heart failure within the 2 weeks prior to screening) or between screening and randomization\n2. History of type 1 diabetes\n3. Major change in diuretic management during 48 hours prior to screening visit or 48 hours prior to randomization visit. (major change defined by doubling of diuretic dose or addition of another diuretic medications)\n4. Significant variability in baseline pulmonary artery diastolic pressures during screening period. Defined as changes greater than +/- 6 mmHg from average pulmonary artery diastolic pressure during week 1 of the screening phase and average pulmonary artery diastolic pressure during week 2 of the screening phase for those patients with an average baseline pulmonary artery diastolic pressure during week 1 of the screening phase of \\<30 mmHg. If the average baseline pulmonary artery diastolic pressure during week 1 of the screening phase is \u226530 mmHg, then \u226520% relative change in average pulmonary diastolic pressure between week 1 and week 2 of the screening phase will be used to define significant variability.\n5. Initiation of hydralazine, long-acting nitrates, beta blockers, angiotensin-converting enzyme inhibitors (ACEIs) , angiotensin II receptor blockers (ARBs) or valsartan/sacubitril in the prior 4 weeks prior to screening\n6. Estimated glomerular filtration rate (eGFR) \\< 30 mL/min/1.73 m2 at the screening visit\n7. Admission for an acute coronary syndrome (ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery within 30 days prior to the screening visit.\n8. Implantation of cardiac resynchronization therapy (CRT) device within the previous 90 days.\n9. Implantation of the CardioMEMs device within the past 2 weeks.\n10. Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy), or planned implantation of cardiac resynchronization therapy (CRT) device within the 90 days after the screening visit.\n11. Participation in any interventional clinical trial (with an investigational drug or device) that is not an observational registry within the 4 weeks prior to the screening visit.\n12. History of hypersensitivity to empagliflozin\n13. For women of child-bearing potential: Current or planned pregnancy or currently lactating\n14. Life expectancy \\<1 year at the screening visit\n15. Patients who are volume depleted based upon physical examination at the time of the screening or randomization visit\n16. Pulmonary artery diastolic pressure \\< 12 mmHg at the time of the screening visit (average of last four measurements available prior to the screening visit).\n17. Patients currently being treated with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin) or having received treatment with any SGLT-2 inhibitor within the 8 weeks prior to the screening visit\n18. Average supine systolic BP \\<90 mmHg at the screening or randomization visit\n19. Current documented history of bladder cancer\n20. Active Gross Hematuria\n21. Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, severe stenotic valve disease, and hypertrophic obstructive cardiomyopathy (HOCM).\n22. History of heart transplant.\n23. Patients on heart transplant list as 1a and 1b status", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "19 Years", "maximumAge": "119 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mikhail Kosiborod, MD", "affiliation": "Saint Luke's Mid America Heart Institute", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Southern California", "city": "Los Angeles", "state": "California", "zip": "90033", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "First Coast Cardiovascular Institute", "city": "Jacksonville", "state": "Florida", "zip": "32256", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "NorthShore University Health System Research Institute", "city": "Evanston", "state": "Illinois", "zip": "60201", "country": "United States", "geoPoint": {"lat": 42.04114, "lon": -87.69006}}, {"facility": "CentraCare Heart and Vascular Center", "city": "Saint Cloud", "state": "Minnesota", "zip": "56303", "country": "United States", "geoPoint": {"lat": 45.5608, "lon": -94.16249}}, {"facility": "St. Francis Hospital", "city": "Roslyn", "state": "New York", "zip": "11576", "country": "United States", "geoPoint": {"lat": 40.79982, "lon": -73.65096}}, {"facility": "Ohio State University", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Sanford Research", "city": "Sioux Falls", "state": "South Dakota", "zip": "57104", "country": "United States", "geoPoint": {"lat": 43.54997, "lon": -96.70033}}, {"facility": "Austin Heart Clinical Research", "city": "Austin", "state": "Texas", "zip": "78756", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Baylor College of Medicine", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Sentara Cardiovascular Research Institute", "city": "Norfolk", "state": "Virginia", "zip": "23507", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}]}, "referencesModule": {"references": [{"pmid": "33550815", "type": "RESULT", "citation": "Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, Lamba S, Bhatt K, Brush J, Civitello A, Gordon R, Jonsson O, Lampert B, Pelzel J, Kosiborod MN. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. Circulation. 2021 Apr 27;143(17):1673-1686. doi: 10.1161/CIRCULATIONAHA.120.052503. Epub 2021 Feb 8."}, {"pmid": "34696602", "type": "DERIVED", "citation": "Nassif ME, Spertus JA, Tang F, Windsor SL, Jones P, Thomas M, Khariton Y, Brush J, Gordon RA, Jermyn R, Jonsson O, Lamba S, Shavelle DM, Kosiborod MN. Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure. Circ Heart Fail. 2021 Nov;14(11):e008446. doi: 10.1161/CIRCHEARTFAILURE.121.008446. Epub 2021 Oct 26. No abstract available."}, {"pmid": "31081589", "type": "DERIVED", "citation": "Nassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23. doi: 10.1111/dom.13678."}], "seeAlsoLinks": [{"label": "Empagliflozin information", "url": "https://druginfo.nlm.nih.gov/drugportal/name/empagliflozin"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "FG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "BG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "69.5", "spread": "12.0"}, {"groupId": "BG001", "value": "62.9", "spread": "13.3"}, {"groupId": "BG002", "value": "66.2", "spread": "12.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "24"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "41"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "12"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "50"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}]}]}, {"title": "Duration of Heart Failure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "5.4", "spread": "5.7"}, {"groupId": "BG001", "value": "7.2", "spread": "5.5"}, {"groupId": "BG002", "value": "6.3", "spread": "5.6"}]}]}]}, {"title": "Prior hospitalization for heart failure", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "57"}]}]}]}, {"title": "Time since last hospitalization for heart failure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1.3", "spread": "0.9"}, {"groupId": "BG001", "value": "1.5", "spread": "1.4"}, {"groupId": "BG002", "value": "1.4", "spread": "1.2"}]}]}]}, {"title": "Ejection fraction", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "46.7", "spread": "14.9"}, {"groupId": "BG001", "value": "40.7", "spread": "17.2"}, {"groupId": "BG002", "value": "43.7", "spread": "16.2"}]}]}]}, {"title": "Ischemic heart disease", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "23"}]}]}]}, {"title": "Type 2 Diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "34"}]}]}]}, {"title": "Atrial Fibrillation", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "37"}]}]}]}, {"title": "Implantable cardioverter defibrillator (ICD)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "36"}]}]}]}, {"title": "Cardiac resynchronization therapy (CRT)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "21"}]}]}]}, {"title": "Pulmonary Artery Diastolic Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "23.3", "spread": "6.9"}, {"groupId": "BG001", "value": "20.5", "spread": "5.7"}, {"groupId": "BG002", "value": "21.9", "spread": "6.4"}]}]}]}, {"title": "Angiotensin-converting enzyme inhibitor / Angiotensin II receptor blocker (ACEI/ARB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "19"}]}]}]}, {"title": "Angiotensin receptor-neprilysin inhibitor (ARNI)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "30"}]}]}]}, {"title": "Beta blockers", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "58"}]}]}]}, {"title": "Hydralazine", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Long-acting nitrates", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "24"}]}]}]}, {"title": "Mineralocorticoid receptor antagonist (MRA)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "29"}]}]}]}, {"title": "Loop diuretics", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "63"}]}]}]}, {"title": "Digoxin", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "Lipid lowering agent", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "50"}]}]}]}, {"title": "Anticoagulant agent", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "29"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "kg/m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "33.5", "lowerLimit": "28.6", "upperLimit": "39.5"}, {"groupId": "BG001", "value": "33.8", "lowerLimit": "29.4", "upperLimit": "40.0"}, {"groupId": "BG002", "value": "33.5", "lowerLimit": "28.8", "upperLimit": "40.0"}]}]}]}, {"title": "Heart rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "bpm", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "70.1", "spread": "10.2"}, {"groupId": "BG001", "value": "72.6", "spread": "9.8"}, {"groupId": "BG002", "value": "71.3", "spread": "10"}]}]}]}, {"title": "Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "128.3", "spread": "19.1"}, {"groupId": "BG001", "value": "120.7", "spread": "20.3"}, {"groupId": "BG002", "value": "124.5", "spread": "19.9"}]}]}]}, {"title": "N-terminal pro b-type natriuretic peptide (NT-proBNP)", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "pg/mL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "865.5", "lowerLimit": "311.0", "upperLimit": "1982.5"}, {"groupId": "BG001", "value": "563.5", "lowerLimit": "153.0", "upperLimit": "1964.0"}, {"groupId": "BG002", "value": "637.0", "lowerLimit": "249.5", "upperLimit": "1964.0"}]}]}]}, {"title": "Brain natriuretic peptide (BNP)", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "pg/mL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "140.0", "lowerLimit": "85.0", "upperLimit": "286.0"}, {"groupId": "BG001", "value": "129.0", "lowerLimit": "51.0", "upperLimit": "378.5"}, {"groupId": "BG002", "value": "140", "lowerLimit": "57.0", "upperLimit": "293.0"}]}]}]}, {"title": "Estimated glomerular filtration rate (eGFR)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "51.2", "spread": "19.7"}, {"groupId": "BG001", "value": "62.7", "spread": "25.5"}, {"groupId": "BG002", "value": "56.9", "spread": "23.3"}]}]}]}, {"title": "Urine Albumin/Creatinine Ratio", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/g", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "101.9", "spread": "187.4"}, {"groupId": "BG001", "value": "201.6", "spread": "688.2"}, {"groupId": "BG002", "value": "149.3", "spread": "491.1"}]}]}]}, {"title": "Hemoglobin A1c (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of hemoglobin", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "6.4", "spread": "1.3"}, {"groupId": "BG001", "value": "6.9", "spread": "1.9"}, {"groupId": "BG002", "value": "6.6", "spread": "1.6"}]}]}]}, {"title": "Hemoglobin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "13.3", "spread": "2.1"}, {"groupId": "BG001", "value": "12.5", "spread": "1.6"}, {"groupId": "BG002", "value": "12.9", "spread": "1.9"}]}]}]}, {"title": "New York Heart Association (NYHA) Class II", "description": "Doctors usually classify patients' heart failure according to the severity of their symptoms. The most commonly used classification system is the New York Heart Association (NYHA) Functional Classification. It places patients in one of four categories based on how much they are limited during physical activity. NYHA Class II means the patient has been classified as having slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "30"}]}]}]}, {"title": "New York Heart Association (NYHA) Class III", "description": "Doctors usually classify patients' heart failure according to the severity of their symptoms. The most commonly used classification system is the New York Heart Association (NYHA) Functional Classification. It places patients in one of four categories based on how much they are limited during physical activity. NYHA Class III indicates the patient has been classified as having Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "34"}]}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire - Overall Summary Score (KCCQ-OS)", "description": "The KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "points", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "60.5", "spread": "16.9"}, {"groupId": "BG001", "value": "61.1", "spread": "27.2"}, {"groupId": "BG002", "value": "60.8", "spread": "22.4"}]}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CS)", "description": "The KCCQ is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "points", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "60.2", "spread": "18.7"}, {"groupId": "BG001", "value": "64.6", "spread": "26.4"}, {"groupId": "BG002", "value": "62.4", "spread": "22.8"}]}]}]}, {"title": "6-minute walk distance", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "meters", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "65"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "237.7", "lowerLimit": "158.5", "upperLimit": "259.1"}, {"groupId": "BG001", "value": "232.1", "lowerLimit": "181.4", "upperLimit": "330.7"}, {"groupId": "BG002", "value": "233.2", "lowerLimit": "170.7", "upperLimit": "304.8"}]}]}]}, {"title": "Insulin (among patients with type 2 diabetes)", "populationDescription": "Insulin use among patients with type 2 diabetes.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "22"}]}]}]}, {"title": "Glucagon-like peptide-1 receptor agonist (GLP-1 RA )(among patients with type 2 diabetes)", "populationDescription": "GLP-1RA use among patients with type 2 diabetes.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Dipeptidyl-peptidase 4 (DPP4) inhibitor (among patients with type 2 diabetes)", "populationDescription": "DPP4-inhibitor use among patients with type 2 diabetes.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Sulfonylurea (among patients with type 2 diabetes)", "populationDescription": "Sulfonylurea use among patients with type 2 diabetes.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "34"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Pulmonary Artery Diastolic Pressure From Baseline to End of Treatment Period (Defined as Average of Pulmonary Artery Diastolic Pressure Measurements Between Weeks 8-12) Between Empagliflozin and Placebo", "description": "Change in pulmonary artery diastolic pressure from baseline to end of treatment period (defined as average of pulmonary artery diastolic pressure measurements between weeks 8-12) between empagliflozin and placebo", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to average between Weeks 8-12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.7", "lowerLimit": "19.6", "upperLimit": "21.7"}, {"groupId": "OG001", "value": "22.2", "lowerLimit": "21.1", "upperLimit": "23.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pulmonary Artery Diastolic Pressure at Each Interim Timepoint (Wks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12) Between Empagliflozin and Placebo.", "description": "Change from baseline in pulmonary artery diastolic pressure at each interim timepoint (wks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Weeks 1-12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Pulmonary artery diastolic pressure - Week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.2", "lowerLimit": "20.4", "upperLimit": "22.1"}, {"groupId": "OG001", "value": "21.4", "lowerLimit": "20.5", "upperLimit": "22.2"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.2", "lowerLimit": "20.4", "upperLimit": "21.9"}, {"groupId": "OG001", "value": "21.5", "lowerLimit": "20.7", "upperLimit": "22.3"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.1", "lowerLimit": "20.3", "upperLimit": "21.9"}, {"groupId": "OG001", "value": "21.7", "lowerLimit": "20.9", "upperLimit": "22.4"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.1", "lowerLimit": "20.2", "upperLimit": "21.9"}, {"groupId": "OG001", "value": "21.8", "lowerLimit": "20.9", "upperLimit": "22.6"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.0", "lowerLimit": "20.1", "upperLimit": "22.0"}, {"groupId": "OG001", "value": "21.9", "lowerLimit": "21.0", "upperLimit": "22.8"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.0", "lowerLimit": "20.1", "upperLimit": "22.0"}, {"groupId": "OG001", "value": "22.0", "lowerLimit": "21.0", "upperLimit": "23.0"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.0", "lowerLimit": "20.0", "upperLimit": "22"}, {"groupId": "OG001", "value": "22.1", "lowerLimit": "21.1", "upperLimit": "23.1"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.0", "lowerLimit": "19.9", "upperLimit": "22.0"}, {"groupId": "OG001", "value": "22.1", "lowerLimit": "21.1", "upperLimit": "23.2"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.0", "lowerLimit": "19.8", "upperLimit": "22.0"}, {"groupId": "OG001", "value": "22.2", "lowerLimit": "21.1", "upperLimit": "23.2"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.8", "lowerLimit": "19.7", "upperLimit": "21.9"}, {"groupId": "OG001", "value": "22.2", "lowerLimit": "21.1", "upperLimit": "23.3"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.7", "lowerLimit": "19.6", "upperLimit": "21.8"}, {"groupId": "OG001", "value": "22.2", "lowerLimit": "21.1", "upperLimit": "23.3"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.5", "lowerLimit": "19.5", "upperLimit": "21.6"}, {"groupId": "OG001", "value": "22.2", "lowerLimit": "21.0", "upperLimit": "23.3"}]}]}, {"title": "Pulmonary artery diastolic pressure - Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.4", "lowerLimit": "19.2", "upperLimit": "21.6"}, {"groupId": "OG001", "value": "22.1", "lowerLimit": "20.9", "upperLimit": "23.3"}]}]}]}, {"type": "SECONDARY", "title": "Change in Pulmonary Artery Systolic Pressure From Baseline to End of Treatment Period (Week 12) Between Empagliflozin and Placebo.", "description": "Change in pulmonary artery systolic pressure from baseline to end of treatment period (week 12) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.4", "lowerLimit": "19.2", "upperLimit": "21.6"}, {"groupId": "OG001", "value": "22.1", "lowerLimit": "20.9", "upperLimit": "23.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pulmonary Artery Systolic Pressure at Each Interim Time Point (Wks 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12) Between Empagliflozin and Placebo.", "description": "Change from baseline in pulmonary artery systolic pressure at each interim time point (wks 1, 2, 3, 4, 5, 6, 7, 8, 9,10,11,12) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Weeks 1-12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Pulmonary artery systolic pressure - Week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.1", "lowerLimit": "42.6", "upperLimit": "45.6"}, {"groupId": "OG001", "value": "43.9", "lowerLimit": "42.4", "upperLimit": "45.3"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.1", "lowerLimit": "42.8", "upperLimit": "45.4"}, {"groupId": "OG001", "value": "44.0", "lowerLimit": "42.7", "upperLimit": "45.2"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.1", "lowerLimit": "42.8", "upperLimit": "45.4"}, {"groupId": "OG001", "value": "44.1", "lowerLimit": "42.8", "upperLimit": "45.3"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.1", "lowerLimit": "42.6", "upperLimit": "45.5"}, {"groupId": "OG001", "value": "44.2", "lowerLimit": "42.7", "upperLimit": "45.6"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.0", "lowerLimit": "42.5", "upperLimit": "45.6"}, {"groupId": "OG001", "value": "44.3", "lowerLimit": "42.7", "upperLimit": "45.8"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.0", "lowerLimit": "42.3", "upperLimit": "45.6"}, {"groupId": "OG001", "value": "44.4", "lowerLimit": "42.8", "upperLimit": "46.0"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "44.0", "lowerLimit": "42.2", "upperLimit": "45.6"}, {"groupId": "OG001", "value": "44.6", "lowerLimit": "42.9", "upperLimit": "46.3"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.8", "lowerLimit": "42.0", "upperLimit": "45.6"}, {"groupId": "OG001", "value": "44.7", "lowerLimit": "42.9", "upperLimit": "46.5"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.7", "lowerLimit": "41.8", "upperLimit": "45.6"}, {"groupId": "OG001", "value": "44.8", "lowerLimit": "42.9", "upperLimit": "46.8"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.6", "lowerLimit": "41.6", "upperLimit": "45.5"}, {"groupId": "OG001", "value": "44.9", "lowerLimit": "42.9", "upperLimit": "46.9"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.4", "lowerLimit": "41.5", "upperLimit": "45.3"}, {"groupId": "OG001", "value": "44.9", "lowerLimit": "43.0", "upperLimit": "46.9"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.3", "lowerLimit": "41.3", "upperLimit": "45.2"}, {"groupId": "OG001", "value": "44.9", "lowerLimit": "43.0", "upperLimit": "46.9"}]}]}, {"title": "Pulmonary artery systolic pressure - Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "43.1", "lowerLimit": "41.0", "upperLimit": "45.1"}, {"groupId": "OG001", "value": "44.9", "lowerLimit": "42.8", "upperLimit": "46.9"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Pulmonary Artery Pressure From Baseline to End of Treatment Period (Week 12) Between Empagliflozin and Placebo.", "description": "Change in mean pulmonary artery pressure from baseline to end of treatment period (week 12) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.3", "lowerLimit": "27.9", "upperLimit": "30.8"}, {"groupId": "OG001", "value": "31.1", "lowerLimit": "29.6", "upperLimit": "32.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Pulmonary Artery Pressure at Each Interim Time Point (Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) Between Empagliflozin and Placebo.", "description": "Change from baseline in mean pulmonary artery pressure at each interim time point (weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline to Weeks 1-12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Pulmonary artery pressure - Week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.1", "lowerLimit": "29.0", "upperLimit": "31.2"}, {"groupId": "OG001", "value": "30.1", "lowerLimit": "29.0", "upperLimit": "31.2"}]}]}, {"title": "Pulmonary artery pressure - Week 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.1", "lowerLimit": "29.1", "upperLimit": "31.1"}, {"groupId": "OG001", "value": "30.2", "lowerLimit": "29.2", "upperLimit": "31.2"}]}]}, {"title": "Pulmonary artery pressure - Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.1", "lowerLimit": "29.1", "upperLimit": "31.0"}, {"groupId": "OG001", "value": "30.4", "lowerLimit": "29.4", "upperLimit": "31.4"}]}]}, {"title": "Pulmonary artery pressure - Week 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.0", "lowerLimit": "29.0", "upperLimit": "31.1"}, {"groupId": "OG001", "value": "30.5", "lowerLimit": "29.5", "upperLimit": "31.6"}]}]}, {"title": "Pulmonary artery pressure - Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.0", "lowerLimit": "28.9", "upperLimit": "31.2"}, {"groupId": "OG001", "value": "30.7", "lowerLimit": "29.5", "upperLimit": "31.8"}]}]}, {"title": "Pulmonary artery pressure - Week 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.0", "lowerLimit": "28.8", "upperLimit": "31.2"}, {"groupId": "OG001", "value": "30.8", "lowerLimit": "29.6", "upperLimit": "32.0"}]}]}, {"title": "Pulmonary artery pressure - Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.0", "lowerLimit": "28.7", "upperLimit": "31.2"}, {"groupId": "OG001", "value": "30.9", "lowerLimit": "29.7", "upperLimit": "32.2"}]}]}, {"title": "Pulmonary artery pressure - Week 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.9", "lowerLimit": "28.6", "upperLimit": "31.2"}, {"groupId": "OG001", "value": "31.0", "lowerLimit": "29.7", "upperLimit": "32.3"}]}]}, {"title": "Pulmonary artery pressure - Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.9", "lowerLimit": "28.5", "upperLimit": "31.2"}, {"groupId": "OG001", "value": "31.1", "lowerLimit": "29.7", "upperLimit": "32.4"}]}]}, {"title": "Pulmonary artery pressure - Week 9", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.8", "lowerLimit": "28.4", "upperLimit": "31.1"}, {"groupId": "OG001", "value": "31.1", "lowerLimit": "29.7", "upperLimit": "32.5"}]}]}, {"title": "Pulmonary artery pressure - Week 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.6", "lowerLimit": "28.2", "upperLimit": "31"}, {"groupId": "OG001", "value": "31.1", "lowerLimit": "29.8", "upperLimit": "32.5"}]}]}, {"title": "Pulmonary artery pressure - Week 11", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.5", "lowerLimit": "28.1", "upperLimit": "30.8"}, {"groupId": "OG001", "value": "31.1", "lowerLimit": "29.7", "upperLimit": "32.5"}]}]}, {"title": "Pulmonary artery pressure - Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.3", "lowerLimit": "27.9", "upperLimit": "30.8"}, {"groupId": "OG001", "value": "31.1", "lowerLimit": "29.6", "upperLimit": "32.5"}]}]}]}, {"type": "SECONDARY", "title": "Change in Heart Failure Related Quality of Life, Using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) From Baseline to Follow-up (Defines as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the Kansas City Cardiomyopathy Questionnaire Overall Summary Score KCCQ-OS, a small but clinically meaningful change is considered to be \u2265 5 points.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) score - 6 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.5", "lowerLimit": "58.0", "upperLimit": "68.9"}, {"groupId": "OG001", "value": "66.6", "lowerLimit": "61.0", "upperLimit": "72.2"}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) score - 12 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "64.2", "lowerLimit": "58.8", "upperLimit": "69.6"}, {"groupId": "OG001", "value": "61.7", "lowerLimit": "56.2", "upperLimit": "67.3"}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS) score - 6 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.6", "lowerLimit": "61.1", "upperLimit": "72.2"}, {"groupId": "OG001", "value": "65.6", "lowerLimit": "60.0", "upperLimit": "71.3"}]}]}, {"title": "Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS) score - 12 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.8", "lowerLimit": "60.3", "upperLimit": "71.2"}, {"groupId": "OG001", "value": "60.2", "lowerLimit": "54.5", "upperLimit": "65.9"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Patients With a \u2265 5 Point Increase From Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the Kansas City Cardiomyopathy Questionnaire Overall Summary Score KCCQ-OS, a small but clinically meaningful change is considered to be \u2265 5 points.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "KCCQ-OS score increase >/= 5 points (6 weeks)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "KCCQ-OS score increase >/= 5 points (12 weeks)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "KCCQ-CS score increase >/= 5 points (6 weeks)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "KCCQ-CS score increase >/= 5 points (12 weeks)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "5"}]}]}]}, {"type": "SECONDARY", "title": "Change in 6 Minute Walk Test From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "Change in 6 minute walk test from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "meters", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "6-minute walk distance - 6 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "202.5", "lowerLimit": "170.9", "upperLimit": "239.8"}, {"groupId": "OG001", "value": "211.2", "lowerLimit": "177.0", "upperLimit": "252.0"}]}]}, {"title": "6-minute walk distance - 12 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "217.4", "lowerLimit": "183.3", "upperLimit": "257.9"}, {"groupId": "OG001", "value": "174.7", "lowerLimit": "146.6", "upperLimit": "208.0"}]}]}]}, {"type": "SECONDARY", "title": "Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "Change in N-terminal pro b-type natriuretic peptide (NT-proBNP) from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "NT-proBNP - 6 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "693", "lowerLimit": "556", "upperLimit": "865"}, {"groupId": "OG001", "value": "655", "lowerLimit": "518", "upperLimit": "830"}]}]}, {"title": "NT-proBNP - 12 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "659", "lowerLimit": "528", "upperLimit": "822"}, {"groupId": "OG001", "value": "802", "lowerLimit": "635", "upperLimit": "1013"}]}]}]}, {"type": "SECONDARY", "title": "Change in Brain Natriuretic Peptide (BNP) From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "Change in brain natriuretic peptide (BNP) from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "BNP - 6 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "143", "lowerLimit": "113", "upperLimit": "180"}, {"groupId": "OG001", "value": "149", "lowerLimit": "116", "upperLimit": "191"}]}]}, {"title": "BNP - 12 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "144", "lowerLimit": "114", "upperLimit": "182"}, {"groupId": "OG001", "value": "167", "lowerLimit": "130", "upperLimit": "214"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Patients With a \u2265 20% Decrease From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.", "description": "Proportion of patients with a \u2265 20% decrease from baseline in N-terminal pro b-type natriuretic peptide (NT-proBNP) at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "NT-proBNP decrease >/= 20% - 6 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "NT-proBNP decrease >/= 20% - 12 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Patients With a \u2265 20% Decrease From Baseline in Brain Natriuretic Peptide (BNP) at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.", "description": "Proportion of patients with a \u2265 20% decrease from baseline in brain natriuretic peptide (BNP) at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo.", "populationDescription": "The number of participants analyzed may differ from the overall number of participants analyzed due to missing data at certain timepoints for some participants.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "BNP decrease >/= 20% - 6 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "BNP decrease >/= 20% - 12 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Patients With Both a \u2265 5 Point Increase From Baseline in KCCQ-OS and a \u2265 20% Decrease From Baseline in NT-proBNP at Either 6 Weeks or 12 Weeks of Follow-up Between Empagliflozin and Placebo.", "description": "Proportion of patients with both a \u2265 5 point increase from baseline in Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) and a \u2265 20% decrease from baseline in N-terminal pro b-type natriuretic peptide (NT-proBNP) at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. For the Kansas City Cardiomyopathy Questionnaire Overall Summary Score KCCQ-OS, a small but clinically meaningful change is considered to be \u2265 5 points.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "14"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Diuretic Medication Adjustments During the Treatment Period Between Empagliflozin and Placebo", "description": "Number of Participants with Diuretic Medication Adjustments During the Treatment Period Between Empagliflozin and Placebo", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Number of patients with no loop diuretic changes", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "26"}]}]}, {"title": "Number of patients with loop diuretic changes", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Change in Hemoglobin A1c From Baseline to Follow-up (Defined as Average of Measurements at 6 and 12 Weeks) Between Empagliflozin and Placebo.", "description": "Change in Hemoglobin A1c from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of hemoglobin", "timeFrame": "Baseline to Week 6 and Week 12", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab"}, {"id": "OG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}]}], "classes": [{"title": "Hemoglobin A1c - 6 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.6", "lowerLimit": "6.3", "upperLimit": "6.9"}, {"groupId": "OG001", "value": "6.5", "lowerLimit": "6.2", "upperLimit": "6.8"}]}]}, {"title": "Hemoglobin A1c - 12 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.8", "lowerLimit": "6.5", "upperLimit": "7.1"}, {"groupId": "OG001", "value": "6.3", "lowerLimit": "6.1", "upperLimit": "6.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were collected for up to 15 weeks. The adverse event collection period started at the time the patient signed consent at their Screening Visit, continued through a 12-week double-blind treatment period after randomization, and ended after completion of a 1-week follow-up period after completion of the double-blind treatment period.", "description": "All adverse events were collected including Serious Adverse Events, Drug Adverse Events, Adverse Events of Special Interest and Urgent Outpatient Heart Failure Visits. A Drug Adverse Events is an adverse event which leads to premature and permanent discontinuation of study drug. Adverse Events of Special Interest include diabetic ketoacidosis, volume depletion, severe hypoglycemic events and non-traumatic lower limb amputations.", "eventGroups": [{"id": "EG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg tab, once daily, for 12 weeks\n\nEmpagliflozin 10 mg Tab: Empagliflozin 10 mg Tab", "deathsNumAffected": 1, "deathsNumAtRisk": 33, "seriousNumAffected": 8, "seriousNumAtRisk": 33, "otherNumAffected": 19, "otherNumAtRisk": 33}, {"id": "EG001", "title": "Placebo", "description": "Empagliflozin matching placebo oral tablet, once daily for 12 weeks\n\nPlacebo Oral Tablet: Empagliflozin matching placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 32, "seriousNumAffected": 9, "seriousNumAtRisk": 32, "otherNumAffected": 16, "otherNumAtRisk": 32}], "seriousEvents": [{"term": "Exacerbation of Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 32}]}, {"term": "Chest Pain", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Head Contusion", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Esophagitis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Groin Abcess", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Hematuria", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Hypotension", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Osteoarthritis - left knee", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Volume Depletion", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Worsening Tricuspid Valve Regurgitation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Endocarditis", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Ventricular Tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "CardioMEMS device recalibration", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}], "otherEvents": [{"term": "Acute Kidney Injury", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}]}, {"term": "Chest Pain", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Cellulitis - bilateral legs", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Congestion", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Contusion - scalp", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Cough", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Dysuria", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Exacerbation of Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 6, "numAffected": 3, "numAtRisk": 32}]}, {"term": "Exertional Angina", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Gastroenteritis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Gout Flare", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}]}, {"term": "Hiccups", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Asymptomatic hypoglycemia", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Hypokalemia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Hypotension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Increased craving for sweets", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Malaise", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Pulmonary Nodule", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Quick Tempered", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Abscess - bilateral - hips, buttocks and upper legs", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Lower left extremity swelling", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Vaginal Yeast Infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Vertigo", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Volume Depletion", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Worsening Gout", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Wound Dehiscence", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}]}, {"term": "Bilateral Handshaking", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Bloating", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Bursitis - left knee", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Cerumen Impaction", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Chest Discomfort", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Decreased renal function", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Deep Vein Thrombosis", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Dizziness", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Dystrophic Toenails", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Flu", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Heart Palpitations", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "ICD Battery Depletion", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Indigestion", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Lightheadedness", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Melena", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Restrictive Ventilatory Defect", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Sick Sinus Syndrome", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Urinary Frequency", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Urinary Tract Infection", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Worsening Edema", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Worsening Urinary Urge Incontinence", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Wrist Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}, {"term": "Contusion - posterior lower left back", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Subsites will not publish until after all multicenter articles have been submitted for publication. Sponsor will have 18 months after the close of the Study at all sites to arrange for the submission of multicenter publications. If such multicenter publications are not submitted within 24 months after conclusion of the Study at all sites, Site Investigator and Subsite may publish the results from the Subsite's data, individually, pursuant to approval by Sponsor and Steering Committee."}, "pointOfContact": {"title": "Study Manager", "organization": "Saint Luke's Hospital of Kansas City", "email": "EMBRACE-HF@saint-lukes.org", "phone": "816-932-9858"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-09-24", "uploadDate": "2021-09-22T18:15", "filename": "Prot_000.pdf", "size": 1923194}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-03-08", "uploadDate": "2021-09-22T18:17", "filename": "SAP_001.pdf", "size": 1007376}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-10-22", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000570240", "term": "Empagliflozin"}], "ancestors": [{"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M258082", "name": "Empagliflozin", "asFound": "Peer", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}